Noul Co

Noul Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Noul Co (376930.KQ) as of Oct 30, 2026 is 117.32 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 90.66 % — a change of 29.40% (higher).

FCF Conversion

117.32 %

YoY

29.40%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Noul Co is 2025 117.32 % . FCF Conversion Rate (FCF/EBITDA) of Noul Co was 2024 90.66 % . It decreases by 29.40% higher compared to the previous year.

The Noul Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
72.64 KRW
Jan 1, 2020
109.98 KRW
Jan 1, 2021
89.81 KRW
Jan 1, 2022
122.85 KRW
Jan 1, 2023
94.90 KRW
Jan 1, 2024
90.66 KRW
Jan 1, 2025
117.32 KRW
The Noul Co FCF Conversion history
YEARFCF ConversionYoY
117.32 %+29.40%
90.66 %-4.47%
94.90 %-22.75%
122.85 %+36.79%
89.81 %-18.34%
109.98 %+51.41%
72.64 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Noul Co Stock analysis

What does Noul Co do? Noul Co., Ltd. generates revenue through the manufacture and sale of blood test diagnostic devices utilizing AI algorithms and diagnostic kits. The company offers regular monthly subscriptions via its integrated web-based remote diagnosis system, targeting healthcare providers and medical facilities seeking advanced diagnostic solutions. Its core products include AI-based diagnostic devices and associated kits, sold directly to clinics and hospitals for use in blood testing procedures. The firm's services are designed to enhance diagnostic accuracy and efficiency through remote access and subscription models. The company's primary revenue streams stem from the sale of physical diagnostic devices and diagnostic kits, alongside recurring subscription fees for its web-based remote diagnosis platform. Healthcare institutions and medical professionals form the key customer segments, purchasing both the hardware and ongoing service access. Noul Co., Ltd. focuses on delivering AI-driven diagnostic tools that integrate seamlessly into existing healthcare workflows, emphasizing convenience and technological innovation for its clients. Noul Co., Ltd. operates exclusively within the healthcare diagnostics sector, providing AI-powered blood test solutions that combine hardware sales with subscription-based software services. The business model relies on initial device purchases followed by continuous revenue from monthly subscriptions, creating a sustainable income stream. This approach ensures long-term engagement with healthcare providers while maintaining a focus on cutting-edge diagnostic technology. Noul Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Noul Co stock

FCF Conversion Rate (FCF/EBITDA) of Noul Co is 117.32 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Noul Co changed from 90.66 % to 117.32 %, representing a 29.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Noul Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Noul Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Noul Co

All Key Metrics — Noul Co